Lance Monroe, MD
Family Medicine · Paragould, ARNPI 1083677058
Payments from drug & device makers
Across 204 payments — averaging $13.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$494
- AbbVie$406
- AstraZeneca$331
- Novo Nordisk$258
- Pfizer$202
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$132
- plus $969 from 26 others
What the payments were for
- Food & beverage$2,792100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 40 | $494 |
| AbbVie(2 entities) | 30 | $406 |
| AstraZeneca | 15 | $331 |
| Novo Nordisk | 18 | $258 |
| Pfizer | 21 | $202 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $132 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $129 |
| Amgen | 7 | $95 |
| Teva Pharmaceuticals USA, Inc. | 7 | $91 |
| Eisai Inc. | 5 | $83 |
| Bayer | 4 | $69 |
| Merck | 4 | $58 |
| Boehringer Ingelheim | 3 | $57 |
| Astellas Pharma US Inc | 3 | $47 |
| Genentech USA, Inc. | 3 | $43 |
| Sunovion Pharmaceuticals Inc. | 10 | $37 |
| Sanofi-aventis U.S. LLC | 3 | $33 |
| Sanofi Pasteur Inc. | 2 | $27 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
| Assertio Therapeutics, Inc. | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Boston Scientific | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| Idorsia Pharmaceuticals US Inc | 1 | $12 |
| Lilly USA, LLC | 1 | $11 |
| Corium, LLC | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,792 in reported general payments places this provider in the 75th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 66 | $65,590 |
| EliquisApixaban | 77 | $61,809 |
| FarxigaDapagliflozin Propanediol | 119 | $58,631 |
| XareltoRivaroxaban | 40 | $28,309 |
| JardianceEmpagliflozin | 30 | $27,886 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $27,373 |
| MounjaroTirzepatide | 24 | $23,887 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $17,455 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 17 | $14,974 |
| EntrestoSacubitril/Valsartan | 20 | $14,478 |
| LokelmaSodium Zirconium Cyclosilicate | 39 | $12,864 |
| JanuviaSitagliptin Phosphate | 20 | $12,570 |
| MyrbetriqMirabegron | 22 | $12,010 |
| Bydureon BciseExenatide Microspheres | 13 | $11,410 |
| LinzessLinaclotide | 13 | $10,304 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Lokelma, Brilinta | $331 | $98,581195 claims |
| Novo NordiskOzempic | $258 | $65,59066 claims |
| PfizerEliquis | $202 | $61,80977 claims |
| Johnson & JohnsonXarelto | $16 | $28,30940 claims |
| Boehringer IngelheimJardiance | $57 | $27,88630 claims |
| GSKTrelegy Ellipta | $494 | $27,37341 claims |
| Lilly USA, LLCMounjaro | $11 | $23,88724 claims |
| MerckJanuvia, Dulera | $58 | $19,43840 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $33 | $14,97417 claims |
| Astellas Pharma US IncMyrbetriq | $47 | $12,01022 claims |
| AbbVieLinzess | $406 | $10,30413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Paragould
- Hetal PatelParagould$147K
- Clarence KempParagould$16K
- Vincent LeeParagould$16K
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Jodi SansonHot Springs$1.7M
- Senthil RaghavanLittle Rock$496K
- Broderick EatonWynne$442K
- Landon HumphreyConway$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.